Relevant bibliographies by topics / Novel targeted therapies

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Novel targeted therapies'

Author: Grafiati
Published: 4 June 2021
Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Novel targeted therapies.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Novel targeted therapies"

1

St Clair, E. William. "Novel targeted therapies for autoimmunity." Current Opinion in Immunology 21, no. 6 (2009): 648–57. http://dx.doi.org/10.1016/j.coi.2009.09.008.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Karpel-Massler, Georg, Trang T. T. Nguyen, Enyuan Shang, and Markus D. Siegelin. "Novel IDH1-Targeted Glioma Therapies." CNS Drugs 33, no. 12 (2019): 1155–66. http://dx.doi.org/10.1007/s40263-019-00684-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Giudice, Valentina, Carmine Vecchione, and Carmine Selleri. "Cardiotoxicity of Novel Targeted Hematological Therapies." Life 10, no. 12 (2020): 344. http://dx.doi.org/10.3390/life10120344.

Full text
Abstract:
Chemotherapy-related cardiac dysfunction, also known as cardiotoxicity, is a group of drug-related adverse events negatively affecting myocardial structure and functions in patients who received chemotherapy for cancer treatment. Clinical manifestations can vary from life-threatening arrythmias to chronic conditions, such as heart failure or hypertension, which dramatically reduce quality of life of cancer survivors. Standard chemotherapy exerts its toxic effect mainly by inducing oxidative stress and genomic instability, while new targeted therapies work by interfering with signaling pathways
APA, Harvard, Vancouver, ISO, and other styles
4

Fullmer, Amber, Hagop Kantarjian, and Elias Jabbour. "Novel and Targeted Therapies in Leukemia." Emerging Cancer Therapeutics 2, no. 2 (2011): 389–409. http://dx.doi.org/10.5003/2151-4194.2.2.389.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Maron, Steven B., and Daniel V. T. Catenacci. "Novel Targeted Therapies for Esophagogastric Cancer." Surgical Oncology Clinics of North America 26, no. 2 (2017): 293–312. http://dx.doi.org/10.1016/j.soc.2016.10.002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Hideshima, Teru, and Kenneth C. Anderson. "Preclinical Studies of Novel Targeted Therapies." Hematology/Oncology Clinics of North America 21, no. 6 (2007): 1071–91. http://dx.doi.org/10.1016/j.hoc.2007.08.013.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Lane, N. "Novel and targeted therapies for OA." Osteoarthritis and Cartilage 20 (April 2012): S3. http://dx.doi.org/10.1016/j.joca.2012.02.613.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Konda, Bhavana, and Lawrence S. Kirschner. "Novel targeted therapies in adrenocortical carcinoma." Current Opinion in Endocrinology & Diabetes and Obesity 23, no. 3 (2016): 233–41. http://dx.doi.org/10.1097/med.0000000000000247.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Argilés, Josep M., Francisco Javier López-Soriano, Britta Stemmler, and Sílvia Busquets. "Novel targeted therapies for cancer cachexia." Biochemical Journal 474, no. 16 (2017): 2663–78. http://dx.doi.org/10.1042/bcj20170032.

Full text
Abstract:
Anorexia and metabolic alterations are the main components of the cachectic syndrome. Glucose intolerance, fat depletion, muscle protein catabolism and other alterations are involved in the development of cancer cachexia, a multi-organ syndrome. Nutritional approach strategies are not satisfactory in reversing the cachectic syndrome. The aim of the present review is to deal with the recent therapeutic targeted approaches that have been designed to fight and counteract wasting in cancer patients. Indeed, some promising targeted therapeutic approaches include ghrelin agonists, selective androgen
APA, Harvard, Vancouver, ISO, and other styles
10

Macfarlane, Robyn J., and Kim N. Chi. "Novel Targeted Therapies for Prostate Cancer." Urologic Clinics of North America 37, no. 1 (2010): 105–19. http://dx.doi.org/10.1016/j.ucl.2009.11.011.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Novel targeted therapies"

1

Bolin, Sara. "Mechanisms of Medulloblastoma Dissemination and Novel Targeted Therapies." Doctoral thesis, Uppsala universitet, Neuroonkologi, 2016. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-300907.

Full text
Abstract:
Medulloblastomas are the most frequent malignant childhood brain tumors, arising in the posterior fossa of children. The overall 5-year survival is 70%, although children often suffer severe long-term side effects from standard medical care. To improve progression-free survival and quality of life for these children, finding new therapeutic targets in medulloblastoma is imperative. Medulloblastoma is divided in to four molecular subgroups (WNT, SHH, Group 3 and Group 4) based on key developmental pathways essential for the initiation and maintenance of tumor development. The MYC family of prot
APA, Harvard, Vancouver, ISO, and other styles
2

Dawson, Jesse. "Prevention of stroke risk stratification and targeted and novel therapies /." Thesis, Connect to e-thesis, 2009. http://theses.gla.ac.uk/851/.

Full text
Abstract:
Thesis (MD.) - University of Glasgow, 2009.<br>MD. thesis submitted to Division of Cardiovascular and Medical Sciences, University of Glasgow, 2009. Includes bibliographical references. Print version also available.
APA, Harvard, Vancouver, ISO, and other styles
3

Tavallai, Mehrad. "INTRODUCING NOVEL COMBINATORIAL TARGETED THERAPIES IN MULTIPLE TYPES OF CANCER." VCU Scholars Compass, 2016. http://scholarscompass.vcu.edu/etd/4088.

Full text
Abstract:
The cancers of liver, colon and breast are amongst the top five most prevalent and most fatal worldwide. As the Raf/MEK/ERK pathway is frequently deregulated in hepatocellular carcinoma (HCC), sorafenib, a Raf kinase inhibitor, became the first systemic therapy approved for the treatment of patients with HCC. However, sorafenib only produced modest effects with low response rates in the clinic. Similarly, regorafenib, which was approved for the treatment of metastatic colorectal cancer (CRC), has had a poor response rate in the clinic. Since phosphodiesterase type 5 has been reported to be ove
APA, Harvard, Vancouver, ISO, and other styles
4

Kouadio, Ange S. "Exploring the therapeutic potential of novel molecular targeted therapies in treating human ovarian cancer." Click here for download, 2008. http://proquest.umi.com/pqdweb?did=1650501211&sid=2&Fmt=2&clientId=3260&RQT=309&VName=PQD.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Ferrari, Mathieu. "Characterisation of scFv A7 reactivity and development of a novel bispecific antibody for targeted therapies in Rheumatoid Arthritis." Thesis, Queen Mary, University of London, 2014. http://qmro.qmul.ac.uk/xmlui/handle/123456789/8975.

Full text
Abstract:
Despite the success of current biological agents, achievement of broader efficacy and improved safety profile remains an unmet need in rheumatoid arthritis therapy. Neovasculogenesis plays a vital role in the progression and perpetuation of rheumatoid arthritis and significant evidence has demonstrated molecular heterogeneity within the endothelium (MVE) of different tissues. The heterogeneity of the synovial MVE can be exploited for the development of organ-specific therapeutic and diagnostic reagents. A novel recombinant antibody fragment, scFv A7, with specificity for human arthritic synovi
APA, Harvard, Vancouver, ISO, and other styles
6

Hernández, Prat Anna 1984. "Antitumor effects of novel targeted therapies (TAK-228 and TAK-117) with high selectivity againts PI3K/AKT/mTOR pathway in bladder cancer : Defining molecular markers." Doctoral thesis, Universitat Pompeu Fabra, 2017. http://hdl.handle.net/10803/664507.

Full text
Abstract:
El càncer de bufeta avançat s'associa amb un mal pronòstic i amb opcions limitades de tractament. Tot i l’èxit recent amb l'ús d'inhibidors immunitaris, no tots els pacients responen a la teràpia i encara hi ha la necessitat d'opcions alternatives. La ruta de PI3K/AKT/mTOR està sobreactivada sovint en aquesta patologia i pot ser un objectiu terapèutic potencial per a la intervenció terapèutica. Es va estudiar l'eficàcia antitumoral del TAK-228, un inhibidor oral de mTORC1 / 2 en models preclínics de càncer de bufeta amb alteracions en la transducció de senyals d'aquesta via. Es va demostrar un
APA, Harvard, Vancouver, ISO, and other styles
7

Gifu, Elena Patricia. "Emergence of cancer stem cells in the early stages of hepatic carcinogenesis and development of innovative models of hepatocellular carcinoma." Thesis, Lyon, 2017. http://www.theses.fr/2017LYSE1319/document.

Full text
Abstract:
Le carcinome hépatocellulaire est un grand problème de santé publique et la troisième de mortalité lié au cancer dans le monde. Il a été démontré qu'au sein des tumeurs se trouve un petite population des cellules cancéreuses avec des propriétés de cellules souches cancéreuses. Elles sont responsables de l'initiation des tumeurs ainsi que de la récidive post-traitement et résistance aux thérapies. Peu de choses sont connues par rapport à la biologie de ces cellules mais l'identification des facteurs favorisant leur existence pourrait conduire vers des nouvelles pistes thérapeutiques.Nous avons
APA, Harvard, Vancouver, ISO, and other styles
8

Han, Yanyan. "Functional characterization of FMNL1 as potential target for novel anti-tumor therapies." Diss., lmu, 2010. http://nbn-resolving.de/urn:nbn:de:bvb:19-112968.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Gracia-Maldonado, Gabriel. "Exploiting the MLL-rearranged leukemia gene signature to identify molecular targets for novel therapies." University of Cincinnati / OhioLINK, 2019. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1573570752309466.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Sallaberry, Pinto Júlia. "Novel markers and targets of collective tumor cell invasion before and after anti-angiogenic therapies." Doctoral thesis, Universitat de Barcelona, 2019. http://hdl.handle.net/10803/666666.

Full text
Abstract:
Local invasion is a key cell-biological event in the metastatic cascade. In response to a changing microenvironment, cancer cells may act using two main strategies of invasion: single cell invasion and collective invasion. Determining how tumor cells initiate and sustain local invasive behavior might help to improve patient diagnosis and lead to the development of new intervention modalities. Therefore, the aim of this thesis is to elucidate which molecular mechanisms are involved in PanNETs invasion before and after anti-angiogenic therapies. Results from our group have demonstrated an irr
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Novel targeted therapies"

1

Dzau, Victor J., and Gabor M. Rubanyi. The endothelium in clinical practice: Source and target of novel therapies. M. Dekker, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Los, Marek, and Spencer B. Gibson, eds. Apoptotic Pathways as Targets for Novel Therapies in Cancer and Other Diseases. Springer-Verlag, 2005. http://dx.doi.org/10.1007/b102187.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Rathore, Ritesh. Novel Chemoradiotherapy Regimens Incorporating Targeted Therapies in Locally Advanced Head and Neck Cancers. INTECH Open Access Publisher, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Grunwald, Peter. Pharmaceutical Biocatalysis: Important Enzymes, Novel Targets, and Therapies. Jenny Stanford Publishing, 2020.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Grunwald, Peter. Pharmaceutical Biocatalysis: Important Enzymes, Novel Targets, and Therapies. Jenny Stanford Publishing, 2020.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Grunwald, Peter. Pharmaceutical Biocatalysis: Important Enzymes, Novel Targets, and Therapies. Jenny Stanford Publishing, 2020.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

Pharmaceutical Biocatalysis: Important Enzymes, Novel Targets, and Therapies. Jenny Stanford Publishing, 2020.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Weller, Michael, Michael Brada, Tai-Tong Wong, and Michael A. Vogelbaum. Astrocytic tumours: diffuse astrocytoma, anaplastic astrocytoma, glioblastoma, and gliomatosis cerebri. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199651870.003.0003.

Full text
Abstract:
Astrocytic gliomas are primary brain tumours thought to originate from neural stem or progenitor cells. They are assigned grades II, III, or IV by the World Health Organization according to degree of malignancy as defined by histology. The following molecular markers are increasingly used for diagnostic subclassification or clinical decision-making: 1p/19q co-deletion status, O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status, and isocitrate dehydrogenase 1 and 2 mutation status. Extent of resection is a favourable prognostic factor, but surgery is never curative. Radiot
APA, Harvard, Vancouver, ISO, and other styles
9

Vincent, Tonia L., and Linda Troeberg. Pathogenesis of osteoarthritis. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0138.

Full text
Abstract:
Understanding pathogenic mechanism in disease is critical for development of targeted therapeutic strategies. Although there are, at this time, only a handful of experimental approaches for treating osteoarthritis (OA), until 10 years ago this disease was almost universally considered an unmodifiable condition. Emerging data during this time, largely fuelled by studies in rodent models, has completely changed the paradigm of disease pathogenesis and has for the first time, generated novel, realistic targets for this highly prevalent and disabling condition. These targets include the aggrecanas
APA, Harvard, Vancouver, ISO, and other styles
10

Kleihues, Paul, Elisabeth Rushing, and Hiroko Ohgaki. The 2016 revision of the WHO classification of tumours of the central nervous system. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199651870.003.0001.

Full text
Abstract:
The revised fourth edition of the WHO classification of Tumours of the Central Nervous System, published in 2016, comprises several newly recognized tumour entities, and a significant restructuring of the classification, mainly based on genetic profiling. Glioblastomas are now classified into two major types. Isocitrate dehydrogenase (IDH)-wildtype glioblastoma (primary glioblastoma IDH-wildtype) develops rapidly de novo without a recognizable precursor lesion. IDH-mutant glioblastoma (secondary glioblastoma IDH-mutant) develops more slowly through malignant progression from diffuse or anaplas
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Novel targeted therapies"

1

Hildebrandt, Bert, Philipp le Coutre, Annett Nicolaou, Konrad Kölble, Hanno Riess, and Bernd Dörken. "Cetuximab: Appraisal of a Novel Drug Against Colorectal Cancer." In Targeted Therapies in Cancer. Springer Berlin Heidelberg, 2007. http://dx.doi.org/10.1007/978-3-540-46091-6_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Myall, Nathaniel J., and Sukhmani K. Padda. "BRAF: Novel Therapies for an Emerging Target." In Targeted Therapies for Lung Cancer. Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-17832-1_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Koczywas, Marianna, and Idoroenyi Amanam. "Novel Therapies for Small Cell Lung Cancer." In Targeted Therapies for Lung Cancer. Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-17832-1_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Ronghe, Milind D., and Dermot Murphy. "Chemotherapy and Novel Cancer Targeted Therapies." In The Surgery of Childhood Tumors. Springer Berlin Heidelberg, 2016. http://dx.doi.org/10.1007/978-3-662-48590-3_9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Chen, Robert W. "Novel Targeted Therapies in Hodgkin Lymphoma." In Molecular Pathology Library. Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-68094-1_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Baek, Kwang-Hyun, Key-Hwan Lim, and Jang-Joon Park. "Deubiquitinating Enzymes as Novel Targets for Cancer Therapies." In Resistance to Targeted Anti-Cancer Therapeutics. Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-06752-0_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Pinho, Andreia V., Jenny H. Lee, and Helen Rizos. "Emerging Novel Therapies in Overcoming Resistance to Targeted Therapy." In Resistance to Targeted Anti-Cancer Therapeutics. Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-21477-7_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Nahta, Rita. "Novel Therapies to Overcome HER2 Therapy Resistance in Breast Cancer." In Resistance to Targeted Anti-Cancer Therapeutics. Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-21477-7_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Kumar, Binayak, Deepu Sharma, Jyotsna Gorantala, and Sri Krishna Jayadev Magani. "Small Molecule-Targeted Therapies for GI Cancers: Success and Failures." In Novel therapeutic approaches for gastrointestinal malignancies. Springer Singapore, 2020. http://dx.doi.org/10.1007/978-981-15-5471-1_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Roden, Dylan F., Jennifer M. Johnson, Petr Szturz, Paolo Bossi, and Athanassios Argiris. "New and Promising Targeted Therapies in First and Second-Line Settings." In Critical Issues in Head and Neck Oncology. Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-63234-2_18.

Full text
Abstract:
AbstractDeeper understanding of the molecular pathogenesis of malignancies, including head and neck squamous cell carcinoma (HNSCC), has led to the investigation of several novel targeted therapies. These therapeutic approaches may eventually replace or complement existing treatment modalities, such as surgery, radiation therapy, and traditional cytotoxic chemotherapy. Epidermal growth factor receptor (EGFR) inhibitors, and specifically cetuximab, are as of now the only class of targeted agents, excluding immune checkpoint inhibitors, with approval in the treatment of HNSCC. Beyond EGFR inhibition, novel therapies under evaluation are directed against vascular endothelial growth factor (VEGF) and VEGF receptor (VEGFR), PI3K/AKT/mTOR pathway, cell cycle regulation (for example, cyclin dependent kinases 4 and 6), HRAS, DNA repair mechanisms, and others. Development of new therapies has to take into consideration the complexity of solid tumors and their heterogeneity. Multitargeted combination therapy approaches may be required in certain cases in order to maximize antitumor effect. Ways to individualize treatment using validated biomarkers are likely to improve outcomes. We review the most relevant molecular targets in HNSCC and provide updates on clinical trial data with promising new targeted agents.
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Novel targeted therapies"

1

Suriano, Robert, Neha Y. Tuli, Jan Geliebter, Raj K. Tiwari, and Marc Wallack. "Abstract 3540: Novel targeted combinational therapies for melanoma." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-3540.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Ebert, Benjamin. "Abstract SY13-03: Novel targeted therapies in myelodysplastic syndrome." In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-sy13-03.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Dolfi, Sonia C., Ann Silk, Bhavna Paratala, et al. "Abstract 4129: Novel oncogenic BRAF fusions and impact on targeted therapies." In Proceedings: AACR Annual Meeting 2017; April 1-5, 2017; Washington, DC. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1538-7445.am2017-4129.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Dawson, Mark A. "Abstract IA10: Targeted therapies as molecular probes for comprehensive preclinical evaluation." In Abstracts: Second AACR Conference on Hematologic Malignancies: Translating Discoveries to Novel Therapies; May 6-9, 2017; Boston, MA. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1557-3265.hemmal17-ia10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Rivera, Sofia, Conchita Vens, Philippe Maingon, et al. "Abstract C220: Combining novel targeted therapies and radiotherapy: A challenge to overcome." In Abstracts: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics--Oct 19-23, 2013; Boston, MA. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1535-7163.targ-13-c220.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Pavia-Jimenez, Andrea, Wenfang Chen, Haley Hill, et al. "Abstract IA10: Renal cancer tumorgrafts: A validated model to evaluate novel targeted therapies." In Abstracts: Patient-Derived Cancer Models: Present and Future Applications from Basic Science to the Clinic; February 11-14, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1557-3265.pdx16-ia10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Tomlinson, Christine C., Christina N. Bennett, Melinda Hollinghead, and Jeffrey E. Green. "Abstract 5774: Identification of novel targeted therapies for human triple-negative breast cancer." In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-5774.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Fukazawa, Takuya, Yutaka Maeda, Huifang Hao, et al. "Abstract 2180: Development of novel targeted therapies for non-small cell carcinoma by novel Midkine inhibitors." In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-2180.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Szot, Christopher S., Christopher B. Arena, Paulo A. Garcia, Rafael V. Davalos, Joseph W. Freeman, and Marissa Nichole Rylander. "A Novel In Vitro Model for Irreversible Electroporation Based Cancer Therapies and Treatment Planning." In ASME 2011 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2011. http://dx.doi.org/10.1115/sbc2011-53929.

Full text
Abstract:
Irreversible electroporation (IRE) is a minimally invasive, localized, non-thermal tissue ablation technique that has shown tremendous promise as an effective cancer therapy option. This procedure uses electrodes to apply a series of short-duration, high intensity electric pulses to a targeted tissue region. These pulses can produce irreversible structural changes in the cell membranes within the targeted region, generating a controllable range of cell death [1].
APA, Harvard, Vancouver, ISO, and other styles
10

Pearson, Jennifer M., Su-Fern Tan, Arati Sharma, et al. "Abstract 48: Acid ceramidase inhibition: A targeted therapy for acute myeloid leukemia." In Abstracts: Second AACR Conference on Hematologic Malignancies: Translating Discoveries to Novel Therapies; May 6-9, 2017; Boston, MA. American Association for Cancer Research, 2017. http://dx.doi.org/10.1158/1557-3265.hemmal17-48.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Novel targeted therapies' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography